Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

Executive Summary

The FDA's cardiovascular safety warning on Abbott's obesity drug Meridia (sibutramine) - which was issued in light of early results from a 10,000 patient strong outcomes study - could mean higher regulatory risk for up-and-coming obesity drugs
Advertisement

Related Content

Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents
Obesity Drug Developers Aim To Navigate Regulatory Backroads
Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use
Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use
REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel
FDA's Woodcock On Obesity Drugs: It's Hard To Fight Mother Nature
Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia
Arena's Lorcaserin Reaches FDA, But Without REMS Proposal
Public Citizen Re-Petitions FDA To Withdraw Obesity Drug Meridia
Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott

Topics

Advertisement
UsernamePublicRestriction

Register

PS051723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel